PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Paediatrician Publishers, LLC 2012-08-01
Saila:Pediatričeskaâ Farmakologiâ
Gaiak:
juvenile idiopathic arthritis
adalimumab
cost-effectiveness analysis
Sarrera elektronikoa:https://www.pedpharma.ru/jour/article/view/302
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak